Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 6/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.37 |
| ▸ | PPARG | P37231 | 7/20 | 0.37 |
| ▸ | PPARD | Q03181 | 7/20 | 0.37 |
| ▸ | PPARA | Q07869 | 7/20 | 0.37 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TLR2 | O60603 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | FABP4 | P15090 | 2/20 | 0.37 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL302058 | 0.87 | EGLN1 (0.41) | SLC22A6LMNATSHRNFKB1PMP22 | |
| SCHEMBL11347415 | 0.81 | CES1 (0.42) | SLC22A6TSHRAKR1B1GPR84PPARG | |
| SCHEMBL13297947 | 0.79 | CES2 (0.44) | SLC22A6TSHRAKR1B1GPR84PPARG | |
| SCHEMBL25224556 | 0.75 | TSHR (0.50) | LMNATSHRALDH1A1MEN1KMT2A | |
| SCHEMBL7315206 | 0.72 | PTPN7 (0.50) | SLC22A6LMNATSHRNFKB1PMP22 | |
| SCHEMBL710828 | 0.71 | PTPN7 (0.57) | LMNATSHRNFKB1PMP22AKR1B1 | |
| Glutarate SCHEMBL1533374 | 0.71 | SLC22A6 (0.92) | SLC22A6LMNATSHRNFKB1PMP22 | |
| SCHEMBL17613179 | 0.69 | SLC22A6 (0.44) | SLC22A6LMNATSHRNFKB1PMP22 | |
| SCHEMBL22029362 | 0.69 | PTPN7 (0.60) | SLC22A6LMNATSHRNFKB1PMP22 | |
| SCHEMBL9551566 | 0.69 | PTPN7 (0.60) | SLC22A6LMNATSHRNFKB1PMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023180189-A1 | MPRO TARGETING ANTIVIRAL COMPOUNDS | EXSCIENTIA AI LIMITED (GB) | 2023-09-28 | — | — | WO | disclosed |
| EP-2403538-B1 | CONJUGATED PROTEINS AND PEPTIDES | POLYTHERICS LTD (GB) | 2017-10-04 | — | — | EP | disclosed |
| EP-2403538-B1 | CONJUGATED PROTEINS AND PEPTIDES | POLYTHERICS LTD (GB) | 2017-10-04 | — | — | EP | disclosed |
| WO-2017064701-A1 | METHODS FOR TOTAL SYNTHESIS OF RESOLVIN E1 | SALZMAN LOVELACE INVESTMENTS, LTD. (IL) | 2017-04-20 | — | — | WO | disclosed |
| US-9415115-B2 | Conjugated proteins and peptides | POLYTHERICS LIMITED (GB) | 2016-08-16 | — | — | US | disclosed |
| US-9415115-B2 | Conjugated proteins and peptides | POLYTHERICS LIMITED (GB) | 2016-08-16 | — | — | US | disclosed |
| US-9415115-B2 | Conjugated proteins and peptides | POLYTHERICS LIMITED (GB) | 2016-08-16 | — | — | US | disclosed |
| US-9315447-B2 | Compositions and methods for the treatment of inflammation | A.T. Resolve Sarl (CH) | 2016-04-19 | — | — | US | disclosed |
| US-9315447-B2 | Compositions and methods for the treatment of inflammation | A.T. Resolve Sarl (CH) | 2016-04-19 | — | — | US | disclosed |
| US-20150216994-A1 | CONJUGATED PROTEINS AND PEPTIDES | ABZENA (CAMBRIDGE) LIMITED (GB) | 2015-08-06 | — | — | US | disclosed |
| US-20110028481-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. | 2011-02-03 | — | — | US | disclosed |
| EP-2276756-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | Merck Sharp & Dohme Corp. (US) | 2011-01-26 | — | — | EP | disclosed |
| EP-2274296-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | Merck Sharp & Dohme Corp. (US) | 2011-01-19 | — | — | EP | disclosed |
| WO-2010100430-A1 | CONJUGATED PROTEINS AND PEPTIDES | POLYTHERICS LIMITED (GB) | 2010-09-10 | — | — | WO | disclosed |
| WO-2009124166-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK & CO., INC. (US) | 2009-10-08 | — | — | WO | disclosed |
| WO-2009124166-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK & CO., INC. (US) | 2009-10-08 | — | — | WO | disclosed |
| WO-2009123870-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK & CO., INC. (US) | 2009-10-08 | — | — | WO | disclosed |
| US-20090253705-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC | 2009-10-08 | — | — | US | disclosed |
| US-20090253705-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC | 2009-10-08 | — | — | US | disclosed |
| WO-2009124167-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK & CO., INC. (US) | 2009-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028481-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | SLC22A6 4031/4885LMNA 1232/4885TSHR 351/4885 |
| US-20090253705-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | SLC22A6 4031/4885LMNA 1232/4885TSHR 351/4885 |
| US-20150216994-A1 | CONJUGATED PROTEINS AND PEPTIDES | CRKL, C1QBP, ARGLU1 | SLC22A6 2830/4885LMNA 3037/4885TSHR 1201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.